Dr. Carolyn Clancy
Dr. Clancy serves as the VHA Deputy Under Secretary for Health (DUSH) for Discovery, Education & Affiliate Networks (DEAN), effective July 22, 2018. Prior to her current position, she served as the Executive in Charge, Veterans Health Administration, with the authority to perform the functions and duties of the Under Secretary for Health. As the Executive in Charge, Dr. Clancy directed a health care system with an annual budget of approximately $68 billion, overseeing the delivery of care to more than 9 million enrolled Veterans. Previously, she served as the Interim Under Secretary for Health from 2014-2015. Dr. Clancy also served as the VHA Deputy Under Secretary for Health for Organizational Excellence, overseeing VHA’s performance, quality, safety, risk management, systems engineering, auditing, oversight, ethics and accreditation programs, as well as ten years as the Director, Agency for Healthcare Research and Quality. In 2015, Dr. Clancy was selected as the Outstanding Federal Executive of the Year by Disabled American Veterans, and in 2018, she was selected as one of the Top 50 Physician Executives by Modern Healthcare.She is a highly experienced and nationally recognized physician executive. Dr. Clancy holds an academic appointment at George Washington University School of Medicine and serves as Senior Associate Editor, Health Services Research. She served as member of the National Quality Forum, Board of Directors, as the Chair of the AQA Alliance and served on the Board of Governors, Patient-Centered Outcomes Research Institute. An elected member of the National Academy of Medicine, Dr. Clancy was most recently presented with the 2014 Quality Champion Award, National Committee for Quality Assurance and was also named as Honorary Fellow, American Academy of Nursing.
John Godfrey is Senior Vice President of Public Policy for Samsung Electronics America, a U.S. subsidiary of Samsung Electronics Co. headquartered in South Korea. Based in Washington, D.C., he leads Samsung’s public policy team in engagement with government and industry, focusing on communications policy, digital television, wireless spectrum, health care, environment, broadband, cybersecurity, privacy and other areas. An active participant in the Consumer Technology Association (CTA), Godfrey is a member and past chair of the CTA Foundation’s Board of Trustees and CTA’s Video Division Board, among other groups. He is also a past chairman of the Board of Directors of the Advanced Television Systems Committee, the standards developing organization for digital television broadcasting. He served on the Federal Communications Commission’s Downloadable Security Technology Advisory Committee in 2015 and the U.S. Access Board’s Electronic and Information Technology Accessibility Advisory Committee in 1998-1999. Prior to joining Samsung in 2006, Godfrey was vice president of government affairs for Pioneer North America; and previously, he was director of government affairs for Sony Electronics. Earlier, he was with the Information Technology Industry Council, a trade association of leading information technology companies; the National Research Council, the policy research arm of the National Academies of Sciences and Engineering; and SRI International.
Dr. Jon Bloom
Dr. Jon Bloom is a board-certified physician and entrepreneur with over 15 years of experience in technology development, patient monitoring, biomedical research, and health care delivery. He is the chief executive officer of Podimetrics, a care management company with the leading solution to help prevent diabetic foot ulcers, one of the most debilitating and costly complications of diabetes. Dr. Bloom co-founded Podimetrics in 2011 while a student at the MIT Sloan School of Management. Podimetrics combines an FDA-cleared SmartMat™ with wraparound care management to spot signs of ulcers, on average, five weeks before they usually would present clinically. By combining cutting-edge technology with best-in-class care management, Podimetrics earns high engagement rates from patients and achieves unparalleled outcomes saving limbs, lives, and money. Dr. Bloom served as a Clinical Assistant Professor and staff anesthesiologist at the University of Pittsburgh Medical Center. He also served as the Director of Global Medical Affairs for Covidien’s Respiratory and Monitoring Solutions division in Boulder, Colorado. Dr. Bloom is a diplomate of the American Board of Anesthesiology, completing residency at the Massachusetts General Hospital. He has co-authored more than 20 peer-reviewed publications with a primary focus on health care economics and perioperative complications. Prior to his career in medicine Dr. Bloom studied cytochrome P450 drug metabolism at The Scripps Research Institute.
Dr. Sharad Verma
Sharad K. Verma, PhD, is the Director of Research and Development for the Neurofibromatosis TherapyAcceleration Program (NTAP), and an Assistant Professor in the Department of Neurology, at The JohnsHopkins University School of Medicine. In these roles, Dr. Verma oversees a portfolio of diverse research projects focused on the discovery and development of therapeutics for the treatment ofneurofibromatosis type 1 (NF1), a rare neurogenetic disorder (incidence 1:2500) at the interface of neurology, oncology, and dermatology. Dr. Verma’s core expertise is in the development of smallmolecule drugs, and additional areas of experience include chemical biology, R&D projectmanagement, and clinical development, for oncology and rare diseases. Prior to joining Johns HopkinsUniversity, Dr. Verma was in the pharmaceutical industry for nearly 15 years first working at Bayer and laterGlaxoSmithKline, serving in various R&D leadership roles in discovery and clinical development.During his industry tenure, Dr. Verma was a member of multiple project teams, which delivered atotal of 6 clinical development candidates (1 FDA approved), of which he was a leader for 2 of theprograms. Dr. Verma is a reviewer for multiple scientific journals, a scientific consultant, and has been a reviewer on various NIH study sections. A native of the San Francisco bay area, Dr. Verma has a BS from the University of California, San Diego, a PhD inChemistry from the University of California, Irvine, and was a NIH Postdoctoral fellow at the University of California, Berkeley (Go Bears!).